Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
FiercePharma11d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Benzinga.com10d
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough ...
Reuters on MSN10d
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Nov 8 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday Canada's health regulator has approved its vaccine for ...
Moderna, Novavax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official
Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next ...